Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
aTyr Pharma, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
ATYR
Nasdaq
2834
atyrpharma.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for aTyr Pharma, Inc.
What A Cancer Vaccine Stumble Means For Moderna Stock
- Nov 20th, 2026 11:29 am
aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the Connective Tissue Oncology Society (CTOS) 2026 Annual Meeting
- Nov 19th, 2026 5:00 am
At $215, Moderna Stock Already Prices In A Comeback
- Nov 17th, 2026 3:38 am
Systemic Sclerosis Market to Exhibit Growth at a 3% CAGR During the Forecast Period (2026–2036) as Emerging Therapies Expand Treatment Opportunities | DelveInsight
- Nov 16th, 2026 11:00 am
aTyr Pharma (ATYR) Stock Fair Value Moves Lower As Phase III Funding Risks Loom
- Nov 13th, 2026 7:09 pm
The Single Most Important Metric For Moderna Stock
- Nov 13th, 2026 1:12 pm
aTyr Pharma to Participate in Upcoming Investor Conferences
- Nov 11th, 2026 6:00 am
What Is Behind The Rise In Moderna Stock?
- Nov 7th, 2026 5:49 am
Atyr Pharma: Q3 Earnings Snapshot
- Nov 5th, 2026 2:26 pm
aTyr Pharma Announces Third Quarter 2026 Results and Provides Corporate Update
- Nov 5th, 2026 2:01 pm
Which Dates Could Move Moderna Stock Most?
- Nov 4th, 2026 2:56 pm
aTyr Pharma Announces Publication of Results from the Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis in The Lancet Respiratory Medicine
- Oct 29th, 2026 6:00 am
aTyr Pharma Announces One-for-40 Reverse Stock Split
- Oct 27th, 2026 7:00 am
aTyr Pharma Announces Research Collaboration with Montefiore Einstein
- Oct 19th, 2026 5:00 am
aTyr Pharma Announces Publication Demonstrating Anti-Fibrotic Effects of ATYR0101 in the Journal of Biological Chemistry
- Oct 13th, 2026 6:00 am
Positive FDA Alignment Boosts ATyr Pharma's Rare Lung Disease
- Sep 24th, 2026 11:31 am
aTyr Pharma FDA Alignment Sets Protocol for Phase 3 Efzofitimod Study in Pulmonary Sarcoidosis
- Sep 24th, 2026 8:59 am
aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis
- Sep 24th, 2026 4:00 am
Sarcoidosis Market Forecast: Emerging Therapies and Increasing Disease Awareness to Drive Expansion by 2036 | DelveInsight
- Sep 8th, 2026 8:31 am
aTyr Pharma Provides Update on Timing of Regulatory Response for Planned Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis
- Sep 1st, 2026 2:36 pm
Scroll